Press Releases

Topics:
  TITLE DATE  
 
 

Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah

2017-10-13

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, Northeast Section in Savannah, October 12 at 4 pm.

 
 
 

Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12

2017-10-10

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to report on the Symposium on Fexapotide Triflutate studies to be held at the Annual Meeting of the American Urological Association Northeastern Section, in Savannah GA this week.

 
 
 

Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting

2017-09-25

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, Northeast Section.

 
 
 

Nymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5

2017-09-14

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, South Central Section.

 
 
 

Nymox Application Validated: Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia

2017-09-14

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce today that the European Member States for Nymox's Marketing Authorization Application (MAA) for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH, prostate enlargement) have accepted the Company’s MAA.

 
 
 

AUA Meeting in Florida September 16 Postponed Due to Hurricane

2017-09-11

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

The September 16 AUA Meeting in Amelia Island, Florida has been postponed due to the hurricane disaster in Florida.

 
 
 

Nymox Announces Private Placements of $3 Million

2017-08-09

 
 
Topic:  Financial
 
 

Nymox Pharmaceutical Corporation is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million. There were no warrants or fees associated with the transactions.

 
 
 

Nymox Announces Symposium for Company's BPH Drug at American Urological Association Meeting in September

2017-08-07

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company's new drug Fexapotide Triflutate will be held at the September meeting of the American Urological Association, Mid-Atlantic Section.

 
 
 

Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials

2017-05-31

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce statistically significant clinical trial results showing that the Company's prostate enlargement (BPH) and prostate cancer drug Fexapotide Triflutate produced clinically important improvements in sexual function in first-line patients who received Fexapotide in the Company's U.S. long-term clinical trials.

 
 
 

NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT

2017-05-10

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079).

 
  Total   380   Records   First   Previous   1 of 38   Next   Last      Go